Efficacy and Safety of Rapamycin to Complex Vascular Anomalies in Pediatric Patients

  • STATUS
    Recruiting
  • End date
    Dec 1, 2022
  • participants needed
    30
  • sponsor
    Zhujiang Hospital
Updated on 18 November 2021

Summary

KHE and TA are rare tumors and some of the cases may lead to life-threatening complications including Kasabach-Merritt Phenomenon. Typically treated with steroids and vincristine, a majority of the cases do not have good prognosis. Complex vascular malformations are always managed by surgery,sclerotherapy and embolization therapy. While many of the cases still lead to complications such as disfigurement, chronic pain, recurrent infections, coagulopathies. Different medical centers are exploring new therapy for these tough problems. This study is plotted to determine the efficacy and safety of rapamycin monotherapy in KHE/TA and complex vascular malformations in pediatric patients.

Description

According to the classification revised in 2014by International Society for the Study of Vascular ISSVA , vascular anomalies are classified into two distinct disease entitiesincluding vascular tumors and vascular malformations differing in their biologic and pathologic features. Vascular tumors include infantile and congenital hemangiomas, Tufted angiomas (TA), and Kaposiform hemangioendotheliomas (KHE). Vascular malformations are classified according to their vascular tissue of origin which include capillary, venous, arteriovenous, lymphatic, and mixed malformations. Infantile hemangiomas, the most common vascular anomaly, generally have a good prognosis due to its specific biological characteristicsa predetermined life cycle from proliferation to subsequent involution). HoweverKHE and TA are rare vascular tumors with incidence less than 1/1000000 and along with complex lymphatic malformations and complex mixed malformationsare difficult to be successfully treated resulting in clinical problems such as disfigurement, chronic pain, recurrent infections, coagulopathies (thrombotic and hemorrhagic,including life-threatening Kasabach-Merritt Phenomenon), organ dysfunction. Rapamycin directly inhibits the mTOR pathway, thereby inhibiting cell proliferation and angio/lymphangiogenesis and is recently applied to refractory vascular . Preclinical data and case reports have confirm that rapamycin is effective for KHE/TA and some slow-flow vascular malformations. The overall goal of this trial is to objectively determine the effectiveness and safety of rapamycin monotherapy in KHE/TA and complex vascular malformations in pediatric patients and to explore the rational doses. In this study, 30 patients (aged from 1 month to 14 years old) diagnosed with KHE/TA or complex vascular that respond poorly to propranolol hydrochloride and corticosteroid are enrolled. Oral rapamycin is given as a monotherapy at a initial dose of 0.8mg/m2, once daily for children under 3 years old and twice daily (every 12 hours) for those above 3 years. And further dosage is adjusted to target a trough concentration of rapamycin in plasma as 10-15ng/ml OR 15-20ng/ml if the efficacy of treatment is not satisfactory with concentration at 10-15ng/ml. One course lasts for 12weeks and no more than 4 courses are given.Volumetric changes as the primary outcome measure will be analysed by magnetic resonance imaging (MRI) and/or ultrasonography. Frequency of adverse events as assessed by CTCAE v4.0 is calculated to evaluate the safety of rapamycin.

Details
Condition Vascular Anomalies
Treatment Treatment with oral rapmycin
Clinical Study IdentifierNCT04598204
SponsorZhujiang Hospital
Last Modified on18 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Diagnosis: All patients must be diagnosed with Kaposiform Hemangioendotheliomas Tufted Angioma or complicated vascular malformation as determined by clinical, radiographic and histologic criteria (when possible)
Patients must have vascular anomalies that respond poorly to propranolol hydrochloride and corticosteroid
Organ function requirements
1 Adequate liver function defined as: Total bilirubin (sum of conjugated and
unconjugated) 1.5 x ULN for age, and SGPT (ALT) <5 x ULN for age, and Serum
albumin > or = 2 g/dL
2 Adequate Bone Marrow Function defined as: Peripheral absolute neutrophil
count (ANC) > or = 1000/microL Hemoglobin > or = 8.0 gm/dL (may receive RBC
transfusions) Platelet count > or = 50,000/microL (transfusion independent
defined as not receiving a platelet transfusion within a 7 day period prior to
enrollment) Note: There is NO platelet requirement for patients with Kasabach-
Merritt Phenomenon 3.3 Adequate Renal Function Defined as
A serum creatinine based on age as follows
years of age maximum serum creatinine (mg/dL) of 0.8 6 < age 10 years of age
maximum serum creatinine (mg/dL) of 1.0 11 < age 15 years of age maximum serum
creatinine (mg/dL) of 1.2 > 15 years of age maximum serum creatinine (mg/dL)
of 1.5 cystatin C equal to or less than the upper limit of normal for the
patient. If cystatin C does not initially meet this criterion, it may be
repeated or a more sensitive screening by nuclear GFR must be 70 ml/min
Urine protein to creatinine ratio (UPC) < 0.3 g/l
\. Patients must be Human Immunodeficiency Virus negative and without
immunodeficiency or infectious disease such as viral hepatitis
\. Patients must have no gastrointestinal disease that would affect the
absorption of rapamycin
\. Performance Status: Karnofsky > or = 50 (>10 years of age) and Lansky > or
= 50 for patients < or = 10 years of age
\. Patients may not be currently receiving strong inhibitors of CYP3A4 or
strong inducers of CYP3A4 and may not have received these medications within 1
week of entry
\. Patients must not have corticosteroid, chemotherapy or radiotherapy within
weeks of entry
\. Guardians must be informed consent

Exclusion Criteria

Known allergy to mTOR inhibitor
Under the treatment of other medicine for vascular anomalies
Known chronic or infectious disease
Patients who received prior per os treatment with an mTOR inhibitor
Known digestive disease that would affect the absorption of rapamycin
Guardians disagree to sign the informed consent
Patients who in the opinion of the investigator would be at risk in the study or would affect the accuracy of the study results.-
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note